Compare Diageo plc (DEO) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Diageo plc vs BIO-TECHNE Corp — how do they compare? Diageo plc trades at $87.51 (market cap $47.54B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: Diageo plc is far larger — about 4.2× BIO-TECHNE Corp's market cap, and Diageo plc pays the higher dividend (2.36%). Which is the better fit depends on your goals — on Pluang, investors hold Diageo plc for 66 Days and BIO-TECHNE Corp for 63 Days on average.
| DEO | TECH | |
|---|---|---|
Market Cap | $47.54B | $11.37B |
Volume | 1,824,704 | 3,153,511 |
Sector | Consumer Staples | Health |
52-Week High | $102.14 | $72.61 |
52-Week Low | $72.47 | $43.31 |
Typical Hold Time | 66 Days | 63 Days |
Enterprise Value | $67.96B | $11.40B |
Dividend Yield | 2.36% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Diageo (DEO) trades at $84.73, down slightly by 0.06% on the day, with a bearish technical signal from moving averages. The company shows solid profitability with a 59.47% gross margin and has beaten EPS estimates in the last three quarters. Recent news highlights marketing initiatives and a CFO transition planned for 2027, while analyst consensus leans positive with 49% buy ratings.
The outlook is mixed: cost-cutting and brand investments support a turnaround, but declining 2026 revenue and net income projections pose risks. Valuation ratios like P/E of 27.19 suggest premium pricing, requiring execution success to justify. Key risks include U.S. market challenges and regulatory scrutiny in regions like India.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Diageo plc
Diageo is a global leader in beverage alcohol with an outstanding collection of brands including Johnnie Walker, Smirnoff, and Guinness. It operates a vast portfolio of spirits and beers across more than 180 countries.
Read more on DEO →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
